These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24398500)

  • 21. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm.
    Johnstone SJ; Adler CH
    Headache; 1998 May; 38(5):366-8. PubMed ID: 9630789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalized botulism: diagnostic problems in a patient treated with botulinum toxin type A.
    Fota-Markowska H; Mitosek-Szewczyk K; Hasiec T
    Acta Ophthalmol Scand; 2007 Mar; 85(2):231-2. PubMed ID: 17305749
    [No Abstract]   [Full Text] [Related]  

  • 24. IncobotulinumtoxinA and Deep Brain Stimulation.
    Soh D; Fasano A
    Can J Neurol Sci; 2019 Sep; 46(5):603-606. PubMed ID: 31196241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
    Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
    J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
    Lee S; Park S; Lew H
    Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
    Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
    Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Botulinum Toxin in Strabismus Treatment.
    Gómez de Liaño R
    J Binocul Vis Ocul Motil; 2019; 69(2):51-60. PubMed ID: 31058579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
    Esposito M; Fasano A; Crisci C; Dubbioso R; Iodice R; Santoro L
    Neurol Sci; 2014 Mar; 35(3):397-400. PubMed ID: 23949734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
    Bladen JC; Favor M; Litwin A; Malhotra R
    Clin Exp Ophthalmol; 2020 Dec; 48(9):1146-1151. PubMed ID: 32710447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: "Botulinum toxin type A for dysthyroid upper eyelid retraction".
    Fay A
    Ophthalmic Plast Reconstr Surg; 2005 Jan; 21(1):81; author reply 81-2. PubMed ID: 15677964
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of essential infantile esotropia with botulinum toxin A: review and recommendations.
    McNeer KW; Tucker MG; Spencer RF
    J Pediatr Ophthalmol Strabismus; 2000; 37(2):63-7; quiz 101-2. PubMed ID: 10779262
    [No Abstract]   [Full Text] [Related]  

  • 33. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
    Silveira-Moriyama L; Gonçalves LR; Chien HF; Barbosa ER
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):221-4. PubMed ID: 16100966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oculinum injection-resistant blepharospasm in young patients.
    Roggenkämper P; Nüssgens Z
    Ophthalmic Plast Reconstr Surg; 1997 Mar; 13(1):73. PubMed ID: 9076788
    [No Abstract]   [Full Text] [Related]  

  • 35. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
    Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin for the treatment of early-onset esotropia in children with cerebral palsy.
    Petrushkin H; Oyewole K; Jain S
    J Pediatr Ophthalmol Strabismus; 2012; 49(2):125. PubMed ID: 22420914
    [No Abstract]   [Full Text] [Related]  

  • 39. Asymmetric blepharospasm with bilateral curtain sign.
    de Souza A; Bhonsle SK
    Eur J Neurol; 2012 Dec; 19(12):e141-2. PubMed ID: 23157244
    [No Abstract]   [Full Text] [Related]  

  • 40. Botox: the poison that heals.
    Khanna S; Jain S
    Int Dent J; 2006 Dec; 56(6):356-8. PubMed ID: 17243469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.